Real-World Analysis of Outcomes of Venetoclax+Azacitidine Versus 7+3 Induction in Acute Myeloid Leukemia.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: acute myeloid leukemia (AML)
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
These findings support restricting V+A to intensive-ineligible patients pending randomized confirmation. [TRIAL REGISTRATION] The authors have confirmed clinical trial registration is not needed for this submission.
OpenAlex 토픽 ·
Acute Myeloid Leukemia Research
Histone Deacetylase Inhibitors Research
Chronic Myeloid Leukemia Treatments
[BACKGROUND] Venetoclax plus azacitidine (V+A) is standard for older, intensive-ineligible patients with acute myeloid leukemia (AML).
APA
Nehemias Guevara Rodriguez, Noemy Coreas Mercado, et al. (2026). Real-World Analysis of Outcomes of Venetoclax+Azacitidine Versus 7+3 Induction in Acute Myeloid Leukemia.. EJHaem, 7(2), e70253. https://doi.org/10.1002/jha2.70253
MLA
Nehemias Guevara Rodriguez, et al.. "Real-World Analysis of Outcomes of Venetoclax+Azacitidine Versus 7+3 Induction in Acute Myeloid Leukemia.." EJHaem, vol. 7, no. 2, 2026, pp. e70253.
PMID
41782644 ↗
Abstract 한글 요약
[BACKGROUND] Venetoclax plus azacitidine (V+A) is standard for older, intensive-ineligible patients with acute myeloid leukemia (AML). Its expanding use in younger, curative-eligible adults lacks comparative evidence against conventional 7+3 induction, raising uncertainty about potential survival compromise.
[METHODS] We performed an age-stratified, retrospective comparative effectiveness study using de-identified TriNetX electronic health records (2018-2025). Adults receiving first-line V+A or 7+3 were propensity-matched 1:1 within prespecified age groups (18-59; ≥60) by demographics, comorbidities, socioeconomic factors, and performance status. The primary endpoint was 1-year all-cause mortality; secondary endpoints included complete remission and ICU admission.
[RESULTS] After matching, 214 younger and 1724 older adults per arm were analyzed. Among younger adults, V+A was associated with significantly higher 1-year mortality versus 7+3 (20.6% vs. 8.9%; HR 2.55), with a number needed to harm of nine. Remission rates favored intensive induction (53.3% vs. 44.9%), while ICU use was similar. In older adults, mortality differences were smaller (23.1% vs. 20.5%; HR 1.34; NNH 38), though remission again favored 7+3.
[CONCLUSION] V+A appears markedly inferior to 7+3 as first-line therapy in younger, curative-eligible AML, producing a nearly fourfold greater harm signal than in older adults. These findings support restricting V+A to intensive-ineligible patients pending randomized confirmation.
[TRIAL REGISTRATION] The authors have confirmed clinical trial registration is not needed for this submission.
[METHODS] We performed an age-stratified, retrospective comparative effectiveness study using de-identified TriNetX electronic health records (2018-2025). Adults receiving first-line V+A or 7+3 were propensity-matched 1:1 within prespecified age groups (18-59; ≥60) by demographics, comorbidities, socioeconomic factors, and performance status. The primary endpoint was 1-year all-cause mortality; secondary endpoints included complete remission and ICU admission.
[RESULTS] After matching, 214 younger and 1724 older adults per arm were analyzed. Among younger adults, V+A was associated with significantly higher 1-year mortality versus 7+3 (20.6% vs. 8.9%; HR 2.55), with a number needed to harm of nine. Remission rates favored intensive induction (53.3% vs. 44.9%), while ICU use was similar. In older adults, mortality differences were smaller (23.1% vs. 20.5%; HR 1.34; NNH 38), though remission again favored 7+3.
[CONCLUSION] V+A appears markedly inferior to 7+3 as first-line therapy in younger, curative-eligible AML, producing a nearly fourfold greater harm signal than in older adults. These findings support restricting V+A to intensive-ineligible patients pending randomized confirmation.
[TRIAL REGISTRATION] The authors have confirmed clinical trial registration is not needed for this submission.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Associations Between Sex, Disease Features and Outcome in Patients With Acute Myeloid Leukemia: A Sex-Stratified Analysis of the GIMEMA AML1310 Trial.
- Immunophenotypic Heterogeneity and Clonal Sweep in Acute Myeloid Leukemia Revealed by Flow Cytometry: A Case Series Study.
- Editorial: Exploiting biomarkers for targeted therapies in acute myeloid leukemia.
- Hyperleukocytosis and Access to Minimal Residual Disease Testing Impact Outcomes in Children With Newly Diagnosed Acute Myeloid Leukemia in Thailand.
- Leukemic appendix with clinical presentation that mimics acute appendicitis.
- Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies.